Septerna, Inc. $SEPN Holdings Trimmed by Checkpoint Capital L.P.

Checkpoint Capital L.P. trimmed its holdings in shares of Septerna, Inc. (NASDAQ:SEPN) by 51.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 283,158 shares of the company’s stock after selling 303,315 shares during the quarter. Septerna accounts for approximately 1.8% of Checkpoint Capital L.P.’s investment portfolio, making the stock its 7th largest holding. Checkpoint Capital L.P.’s holdings in Septerna were worth $5,326,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Septerna by 116.7% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 222,702 shares of the company’s stock worth $2,354,000 after purchasing an additional 119,953 shares during the last quarter. Avoro Capital Advisors LLC increased its stake in Septerna by 8.1% in the 3rd quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock worth $25,158,000 after buying an additional 100,000 shares during the period. Rhumbline Advisers lifted its holdings in Septerna by 22.5% during the 2nd quarter. Rhumbline Advisers now owns 28,572 shares of the company’s stock valued at $302,000 after buying an additional 5,254 shares in the last quarter. Boothbay Fund Management LLC bought a new stake in Septerna during the 2nd quarter valued at about $255,000. Finally, CW Advisors LLC purchased a new stake in Septerna in the 2nd quarter valued at about $133,000.

Analysts Set New Price Targets

SEPN has been the topic of a number of research analyst reports. JonesTrading assumed coverage on shares of Septerna in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Thursday, January 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $60.00 price target on shares of Septerna in a report on Tuesday. Wall Street Zen cut Septerna from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Zacks Research upgraded Septerna from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Septerna Price Performance

NASDAQ:SEPN opened at $25.14 on Friday. Septerna, Inc. has a 1-year low of $4.66 and a 1-year high of $32.63. The company has a 50-day moving average of $26.78 and a 200 day moving average of $23.46. The firm has a market cap of $1.13 billion, a PE ratio of -22.65 and a beta of 3.46.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, March 9th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). Septerna had a negative net margin of 106.37% and a negative return on equity of 15.85%. The business had revenue of $24.12 million for the quarter, compared to analysts’ expectations of $20.44 million. Sell-side analysts anticipate that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Samira Shaikhly sold 70,453 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total value of $1,979,729.30. Following the completion of the transaction, the insider owned 793 shares of the company’s stock, valued at $22,283.30. The trade was a 98.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total value of $115,880.00. Following the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $5,046,834.73. This represents a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.30% of the stock is currently owned by company insiders.

More Septerna News

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $40.00 price target on SEPN, signaling continued analyst conviction in the company’s longer‑term upside despite the cuts. MarketBeat SEPN page
• Neutral Sentiment: Coverage roundup: a Globe and Mail piece highlights mixed analyst views on several tech names including Septerna, underscoring market disagreement about timing and magnitude of recovery. Analysts Conflicted on These Technology Names
• Neutral Sentiment: HC Wainwright published multi‑quarter 2027 EPS projections (Q1–Q4 2027 and FY2027), providing a forward framework for the next fiscal year but not materially changing the firm’s Buy stance. MarketBeat SEPN page
• Negative Sentiment: HC Wainwright cut Q1–Q4 2026 quarter estimates (Q1 to ($0.46), Q2 to ($0.55), Q3 to ($0.62), Q4 to ($0.70)), lowering FY2026 EPS to ($2.34) from ($1.67). The downward revisions widen expected near‑term losses and create pressure on sentiment. MarketBeat SEPN page

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.